Shots:

• Denovo has licensed the global rights for idalopirdine including all rights to develop- manufacture and commercialize idalopirdine for all indications. Lundbeck gets an option to reacquire idalopirdine.
• If Lundbeck exercise the option- both the companies will share rights of the product in China and if not- Denovo will retain all global rights to the product
• Idalopirdine (DB109) is an oral antagonist of the serotonin (5-HT6) receptor and is hypothesized to be involved in AD- schizophrenia- and other indications. The therapy is currently being evaluated in multiple studies encompassing 2500+ subjects

  | Ref: PRNewswire | Image: PR Newswire